Dr. John Cush RheumNow
2 years 2 months ago
IL-17 inhibitor Brodalumab is not often talked about, but its approved for PsO & PsA. German study of 227 PsO w/ 37 PsA pts Rx w/ BRO - good, rapid response by 3 mos. 1 year drug survival rate was 76.2%, (mean discontinuation=8.3 mos. https://t.co/4byFoc96Zs https://t.co/sPomX0s8aa
Insurance claims data showed that patients with autoimmune disorders who took Janus kinase (JAK) inhibitors had lower rates of age-related macular degeneration (AMD), hinting that the drugs might treat the common eye disease.
The journal Pain has shown geographic differences in arthritis-attributable pain, arthritis-related outcomes mostly clustered in the Deep South and Appalachia, while severe arthritis pain is more prevalent in the Southwest, Pacific Northwest, Georgia, Florida, and Maine.
Dr. John Cush RheumNow
2 years 2 months ago
192 RA pts on MTX: GI Sxs studied w/ MISS (MTX intolerance severity score). GI intolerance seen in 56%, Nausea & pain post-MTX most common. More in afro-descendants, w/ FM, Steroids, or JAKi. MISS results unrelated to Route, Gi Dz, age, MTX dose https://t.co/EROmZQo1Zs https://t.co/SOMzzXXj0b
Dr. John Cush RheumNow
2 years 2 months ago
Updated EULAR Recommendations on the Treatment of Systemic Sclerosis
Medscape has published an overview to the 2024 updated recommendations for the treatment of SSc presented in Vienna at EULAR 2024.
https://t.co/U0usOgajFQ https://t.co/Hos3mu7rVE
Dr. John Cush RheumNow
2 years 2 months ago
ACR Comments on CMS Proposed 2025 Physician Payment Rule
The American College of Rheumatology (ACR) shared the following initial reaction to the proposed CY 2025 Medicare Physician Fee Schedule (MPFS) and Quality Payment Program rule.
https://t.co/l5aUWiCtQE https://t.co/7jQdouVRbm
Dr. John Cush RheumNow
2 years 2 months ago
Febuxostat is assoc w/ a reduced risk of kidney events and slower decline in eGFR. Metanalysis of 16 RCTs, shows febuxostat w/a reduced risk of kidney events (RR=0.56) & slower decline in eGFR; & reduced urine albumin to creatinine ratio https://t.co/GQ8UopbA88 https://t.co/WQskc1yZ02
Dr. John Cush RheumNow
2 years 2 months ago
IRIS-RA, a failed phase 2 study of Nipocalimab, an anti-FcRn mAb severe active RA not responding to TNFi. 53 seropos. RA pts did not achieve primary endpt of better DAS28-CRP at Wk 12 (but Nipo was numerically better & signif lowered RF, CCP, but not CRP) https://t.co/52HLsfpKLS https://t.co/eEifXA6MpP
Johns Hopkins Hospital in Baltimore has been named the top hospital for rheumatology by U.S. News & World Report. This is the 7th year in a row they have held this spot.The top 5 rheumatology hospitals are largely the same as last year (with some minor shuffling) and includes the Johns Hopkins Hospital, Cleveland Clinic, Hospital for Special Surgery (HSS), Brigham Hospital, and Mayo Clinic.
Dr. John Cush RheumNow
2 years 2 months ago
Pathogenesis of Autoimmune Liver Disease (ALDs)
ALDs, including autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC), are complex conditions involving the liver's immune-mediated damage
https://t.co/acgwwglKve https://t.co/ZDpF1VhBlc
Dr. John Cush RheumNow
2 years 2 months ago
Medscape review of new Gout research from EULAR 2024
- Phase 3 trial program for SEL-212
- Safety of SEL-212
- New Selective URAT1 Inhibitors - ruzinurad & AR882 https://t.co/szVRO2sqpu https://t.co/B9LcdpeCGd
Dr. John Cush RheumNow
2 years 2 months ago
Recurrent chronic monarthritis treatment with microwave ablation (MWA). 22 pts, 24 knees requiring median 5 IA aspirations in the last 6 mos.(total 129) decreased to 7 total in 6 mos post MWA ((0.89 vs 0.03/mo, P < 0.001). No complication. https://t.co/M2N0eFFKvL https://t.co/EOKUfudtSS
Medscape has published an overview to the 2024 updated recommendations for the treatment of systemic sclerosis (SSc) presented in Vienna at EULAR 2024 by Professor Francesco Del Galdo, MD, PhD on behalf of a 27 member task force.
The American College of Rheumatology (ACR) shared the following initial reaction to the proposed CY 2025 Medicare Physician Fee Schedule (MPFS) and Quality Payment Program rule.
